Biogen

Showing 15 posts of 112 posts found.

biogen_austria_238

Biogen’s Spinraza to go before NICE

January 22, 2018
Sales and Marketing Biogen, Spinraza, biotech, drugs, pharma, pharmaceutical

Biogen received marketing approval from the European Commission for Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA), in May …

nerve-cell-2213009_960_720

Eisai and Biogen Alzheimer’s drug stumbles at P2

December 21, 2017
Medical Communications, Research and Development Biogen, Eisai, biotech, drugs, pharma, pharmaceutical

Only a few months ago, it was announced that Eisai had decided to opt into the development process of BAN2401. …

samsung_bioepis_engineer_4

Samsung completes hat-trick of big biosimilar approvals

August 25, 2017
Medical Communications, Sales and Marketing Biogen, Samsung Bioepis, biosimilars, biotech, drugs, pharma, pharmaceutical

Samsung Bioepis has announced that it, alongside its partner Biogen, has secured European Commission approval for its biosimilar version of …

anabella_villalobos

Biogen steal away Pfizer VP to boost R&D plans

August 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Pfizer, biotech, drugs, pharma, pharmaceutical

Pfizer has had a tough time keeping hold of its Vice President’s involved in R&D of late, losing high-profile researcher, …

shutterstock_138095450

New data shows pharma has not cut back on controversial payments to physicians

July 6, 2017
Medical Communications, Sales and Marketing Allergan, Biogen, Celgene, Sanofi, Valeant

Despite increasing controversy arising over the years due to the questionable relationship between physicians and pharma and the money which …

kress

Biogen appoint new Head of Global Therapeutic Operations

June 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Jean-Paul Kress

Biogen announced that Jean-Paul Kress has been appointed to the position of Executive Vice President and President, International, and Head …

1491927276280

Alexion secures ex-Biogen Chief Financial Officer

June 14, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alexion, Biogen, appointment

Alexion Pharmaceuticals has announced that it has snatched up Biogen’s long-serving Chief Financial Officer Paul Clancy and will instate him …

joe-ciaffoni-biogen-750xx2574-1445-0-143

Collegium bring in former Biogen SVP as new COO

May 31, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Collegium pharmaceutical

Collegium Pharmaceutical has announced the appointment of Joseph Ciaffoni to the position of Executive Vice President and Chief Operating Officer. …

EMA gives positive opinion on Biogen’s spinal muscular atrophy drug Spinraza

April 25, 2017
Manufacturing and Production, Sales and Marketing Biogen, Ionis, Spinraza, spinal muscular atrophy

Biogen has revealed that Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA) , has received a positive opinion from …

roche_close

First treatment for form of MS approved by FDA

March 30, 2017
Sales and Marketing Biogen, Genentech, MS, Roche

In big news for sufferers of MS and the company that developed the drug, Roche subsidiary Genetech, the FDA has …

anirvan_ghosh

Biogen swoops to appoint Ex-Roche Vice President

March 16, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen

Biogen have appointed Anirvan Ghosh to the position of Senior Vice President of research and Early Development. Ghosh is slated …

NICE reverses decision on medication for relapsing multiple sclerosis

March 16, 2017
Sales and Marketing Biogen, zinbryta

The current topic of discussion regarding NICE is how its recent changes will impact patient access to medicine but, away …

abbvie_0

UK High Court rules against AbbVie’s Humira patents

March 6, 2017
Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar

The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …

biogen_austria_238

Biogen shells out $1.25bn to protect best-selling MS drug

January 18, 2017
Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera

Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …

Biogen’s gains late-year drug approval first for controversially expensive drug

January 3, 2017
Manufacturing and Production, Sales and Marketing Biogen, FDA

The FDA squeezed in one last approval before the year ended with the first approval for a drug to treat …

Latest content